Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Elevated lipoprotein-associated phospholipase A2 is associated with progression of nonculprit lesions after percutaneous coronary intervention.

Xin H, Gong HP, Cai SL, Ning XF, Liu S, Chen ZY, Lian ZX, Zhang R, Zhang QF, Kang WQ, Ge ZM.

Tohoku J Exp Med. 2013;230(2):97-102.

2.

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.

Jabor B, Choi H, Ruel I, Hafiane A, Mourad W, Genest J.

Can J Cardiol. 2013 Dec;29(12):1679-86. doi: 10.1016/j.cjca.2013.09.026. Epub 2013 Oct 2.

PMID:
24267807
3.

Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Stankovic S, Asanin M, Trifunovic D, Majkic-Singh N, Miljković A, Ignjatovic S, Mrdovic I, Matic D, Savic L, Ostojic M, Vasiljevic Z.

Clin Lab. 2012;58(11-12):1135-44.

PMID:
23289182
4.

Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

Möckel M, Müller R, Vollert J, Müller C, Danne O, Gareis R, Störk T, Dietz R, Koenig W.

Clin Res Cardiol. 2007 Sep;96(9):604-12. Epub 2007 Jun 27.

PMID:
17593313
5.
6.

Higher lipoprotein-associated phospholipase A2 levels are associated with coronary atherosclerosis documented by coronary angiography.

Dohi T, Miyauchi K, Ohkawa R, Nakamura K, Thuboi S, Ogita M, Miyazaki T, Nishino A, Yokoyama K, Kurata T, Yatomi Y, Daida H.

Ann Clin Biochem. 2012 Nov;49(Pt 6):527-33. doi: 10.1258/acb.2012.011252. Epub 2012 Aug 29.

PMID:
22933444
7.

Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.

Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Ohkawa R, Nakamura K, Yanagisawa N, Tsuboi S, Ogita M, Yokoyama K, Kurata T, Yatomi Y, Daida H.

Atherosclerosis. 2011 Dec;219(2):907-12. doi: 10.1016/j.atherosclerosis.2011.09.019. Epub 2011 Sep 17.

PMID:
22024276
8.

Long-term percutaneous coronary intervention rates and associated independent predictors for progression of nonintervened nonculprit coronary lesions.

Park MW, Seung KB, Kim PJ, Park HJ, Yoon SG, Baek JY, Koh YS, Jung HO, Chang K, Kim HY, Baek SH.

Am J Cardiol. 2009 Sep 1;104(5):648-52. doi: 10.1016/j.amjcard.2009.04.052.

PMID:
19699339
9.

Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort.

Li N, Li S, Yu C, Gu S.

Postgrad Med. 2010 Jul;122(4):200-5. doi: 10.3810/pgm.2010.07.2187.

PMID:
20675983
10.

Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome?

Gu X, Hou J, Yang S, Yu H, Tian J, Liu F, Li N, Yu B, Jang IK.

Coron Artery Dis. 2014 Jan;25(1):10-5. doi: 10.1097/MCA.0000000000000041.

PMID:
24089018
11.

Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina.

Gajos G, Zalewski J, Mostowik M, Konduracka E, Nessler J, Undas A.

Nutr Metab Cardiovasc Dis. 2014 Apr;24(4):434-9. doi: 10.1016/j.numecd.2013.09.011. Epub 2013 Nov 1.

PMID:
24555913
12.

Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.

White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A; LIPID Study Investigators.

J Am Heart Assoc. 2013 Oct 23;2(5):e000360. doi: 10.1161/JAHA.113.000360.

13.

Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.

Charniot JC, Khani-Bittar R, Albertini JP, Giral P, Cherfils C, Cosson C, Guillerm E, Leprince P, Gandjbakhch I, Bonnefont-Rousselot D.

Int J Cardiol. 2013 Sep 20;168(1):132-8. doi: 10.1016/j.ijcard.2012.09.054. Epub 2012 Oct 24.

PMID:
23103135
14.

Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.

Woudstra P, Damman P, Kuijt WJ, Kikkert WJ, Grundeken MJ, van Brussel PM, Stroobants AK, van Straalen JP, Fischer JC, Koch KT, Henriques JP, Piek JJ, Tijssen JG, de Winter RJ.

PLoS One. 2014 May 1;9(5):e96251. doi: 10.1371/journal.pone.0096251. eCollection 2014.

15.

Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain.

Dullaart RP, van Pelt LJ, Kwakernaak AJ, Dikkeschei BD, van der Horst IC, Tio RA.

Clin Chim Acta. 2013 Sep 23;424:136-40. doi: 10.1016/j.cca.2013.05.026. Epub 2013 Jun 10.

PMID:
23756128
16.

C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome.

Nakachi T, Kosuge M, Hibi K, Ebina T, Hashiba K, Mitsuhashi T, Endo M, Umemura S, Kimura K.

Circ J. 2008 Dec;72(12):1953-9. Epub 2008 Oct 29.

17.

Nonculprit lesion progression in patients with ST elevation myocardial infarction after primary percutaneous coronary intervention.

Wang J, Liu JH, Zhu XL, Zhang M, Wang SP, Zheng Z.

Int Heart J. 2014;55(1):48-52. Epub 2014 Jan 27.

18.

Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome?

Holst-Albrechtsen S, Kjaergaard M, Huynh AN, Sorensen JK, Hosbond S, Nybo M.

Curr Cardiol Rev. 2013 Nov;9(4):310-5. Review.

19.

Unexpected inverse relationship between impaired glucose metabolism and lipoprotein-associated phospholipase A2 activity in patients with stable vascular disease.

Mayer O Jr, Seidlerová J, Filipovský J, Timoracká K, Bruthans J, Vaněk J, Cerná L, Wohlfahrt P, Renata C, Trefil L.

Eur J Intern Med. 2014 Jul;25(6):556-60. doi: 10.1016/j.ejim.2014.05.010. Epub 2014 Jun 12.

PMID:
24930071
20.

[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].

Sertić J, Skorić B, Lovrić J, Bozina T, Reiner Z.

Acta Med Croatica. 2010 Oct;64(4):237-45. Review. Croatian.

PMID:
21688606

Supplemental Content

Support Center